Dr. Edward P. Monaghan

Angestellt, President/Owner, SOAR Pharmaceutical Development Services

Rancho Santa Margarita, Vereinigte Staaten

Werdegang

Berufserfahrung von Edward P. Monaghan

  • Bis heute 16 Jahre und 6 Monate, seit 2008

    Vice President, Clinical Operations

    TRF Pharma, Inc.; Burlingame, CA

    Responsible for generation of INDs, interactions with the FDA, and development and oversight of clinical programs for a novel treatment of pain caused by sickle cell disease.

  • Bis heute

    President/Owner

    SOAR Pharmaceutical Development Services

  • 6 Monate, Mai 2007 - Okt. 2007

    Head, Clinical & Regulatory

    N.V. Organon; Irvine, CA

    Part of Organon transition team following acquisition of Kadmus' technology.

  • 2002 - 2007

    Vice President, Drug Development

    Kadmus Phamaceuticals, Inc.

    Responsible for generation of INDs and CTAs, interactions with the FDA and TPD, and development and oversight of preclinical toxicology and clinical programs for novel CNS-active compounds for therapeutic indications including pain, depression, and anxiety. Led to successful sale of the technology, valued at up to $150 MM.

  • 1992 - 2002

    Senior Medical Research Specialist

    Serono, Inc., Norwell, MA

    Led an international Phase III tria (EVIDENCE) comparing two active treatments for MS. Directed clinical, data management, biostatistics, and regional CRA activities. Managed a $40MM study budget and surpassed very aggressive timelines.

  • 1995 - 1999

    Associate Director, Clinical Research

    CoCensys, Inc.; Irvine, CA

    Led development activities for novel treatment of epilepsy that included presenting to FDA, NIH, and potential partners, preparing INDs and IBs, designing and implementing Phase I and II trials, hiring and training clinical staff, and establishing intra- and inter-departmental Standards Operating Procedures.

  • 1992 - 1995

    Principal Clinical Research Associate

    Allergan Inc.; Irvine, CA

    Led Phase II and IV studies in neuro-rehabilitation, including protocol development, site selection/initiation, contract negotiation, investigator meetings, monitoring, data analysis, and report writing.

Sprachen

  • Englisch

    -

21 Mio. XING Mitglieder, von A bis Z